NLS Pharmaceutics AG (NLSP)

Market Cap	4.95M
Revenue (ttm)	n/a
Net Income (ttm)	-15.47M
Shares Out	39.56M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,432
Open	0.129
Previous Close	0.133
Day's Range	0.120 - 0.130
52-Week Range	0.113 - 1.530
Beta	-0.84
Analysts	Hold
Price Target	n/a
Earnings Date	May 7, 2024

About NLSP

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of AD...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 29, 2021
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: NLSP